Adverse event totals12

The totals the trial posted for each group.

1 to 12 of 12

Total	Group	Affected	At risk
Total, all-cause mortality	Phase I - Buprenorphine Initiation	0	27
Total, all-cause mortality	Phase II - Gabapentin + Buprenorphine	0	13
Total, all-cause mortality	Phase II - Gabapentin + Placebo	0	14
Total, all-cause mortality	Phase II - Buprenorphine Taper	0	27
Total, other adverse events	Phase I - Buprenorphine Initiation	2	27
Total, other adverse events	Phase II - Gabapentin + Buprenorphine	12	13
Total, other adverse events	Phase II - Gabapentin + Placebo	12	14
Total, other adverse events	Phase II - Buprenorphine Taper	0	27
Total, serious adverse events	Phase I - Buprenorphine Initiation	0	27
Total, serious adverse events	Phase II - Gabapentin + Buprenorphine	0	13
Total, serious adverse events	Phase II - Gabapentin + Placebo	0	14
Total, serious adverse events	Phase II - Buprenorphine Taper	0	27

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02737826/event-totals